Antibody Drug Conjugates Market Size & Growth (2019 – 2024):
According to the report, the Size of the Global Antibody Drug Conjugates Market is valued at USD 11.8 Billion in 2019 and estimated to be growing at a CAGR of 24.74%, to reach USD 35.6 Billion by 2024.
MARKET OVERVIEW
An antibody-drug conjugate (ADC) is a biologically active drug used as targeted therapy in the treatment of cancer that is highly potent drugs of the biopharmaceutical industry. These drugs are chemically complex molecules intended to kill the cancer cells in the body which composed of an antibody that is biologically linked to anticancer drugs. These drugs target multiple pathways and reduce the risk of developing treatment-resistant disorders in the body.
By the mechanism of action, the drugs are segmented into IgG1 antibodies and HER2 antibodies which affect different pathogens like bacteria, fungi, and viruses in the body. Antibody-drug conjugates are widely accepting by several small and big pharmaceutical companies that are filling gaps between many oncology product pipelines. These drugs are also used in many other applications like metabolic disorders, cardiovascular, central nervous system, life science research tools, medical imaging, and vaccines.
Factors like the rise in cancer incidences, changing lifestyles, high investments by the companies in the pipeline analysis, cancer-killing ability and research development of ADCs, growing biomedical industry, new product innovations, and technological advancements are driving the Global Antibody Drug Conjugates Market. However, the high cost of production of ADCs and stringent regulations for product approval are hindering the growth of the market.
REPORT COVERAGE
|
REPORT METRIC
|
DETAILS
|
|
Market Size Available
|
2018 – 2024
|
|
Base Year
|
2018
|
|
Forecast Period
|
2019 - 2024
|
|
Segments Covered
|
By Pipeline, Technology, End-User, Region
|
|
Various Analyses Covered
|
Global, Regional & Country Level Analysis, Segment-Level Analysis, DROC, PESTLE Analysis, Porter’s Five Forces Analysis, Competitive Landscape, Analyst Overview on Investment Opportunities
|
|
Regions Covered
|
North America, Europe, APAC, Latin America, Middle East & Africa
|
|
Market Leaders Profiled
|
Seattle Genetics, Genentech, Takeda Pharmaceuticals, F. Hoffmann-La Roche, Bayer Healthcare, Agensys, Inc., Immunogen, Novartis, Oxford Biotherapeutics, and Synthon Biopharmaceuticals.
|
This market research report on Global Antibody Drug Conjugates Market has been segmented and sub-segmented into the following categories and analyzed market size and forecast until 2024.
Antibody Drug Conjugates Market - By Pipeline:
- Phase
- Mode of action
- Igg1 antibodies
- HER2 antibodies
- Technology
- Linker
Antibody Drug Conjugates Market - By Technology:
- Seattle Genetics
- Immunogen
- Immunomedics
Antibody Drug Conjugates Market - By End User:
- Research institutes
- Hospitals
- Clinics
Regional Analysis:
North America is dominating the global market due to the presence of large companies in this area and their high investment in the cancer product pipelines. Asia-Pacific is the fastest-growing region with a high CAGR owing to the rise in the prevalence of cancer and emerging economies like China and India.
Key Players Operating the Global Antibody-Drug Conjugate Market Profiled in the Report are:
- Seattle Genetics
- Genentech
- Takeda Pharmaceuticals
- Hoffmann-La Roche
- Bayer Healthcare
- Agensys, Inc.,
- Immunogen
- Novartis
- Oxford Biotherapeutics
- Synthon Biopharmaceuticals
- Introduction
- Antibody Drug Conjugates Market Definition
- Study Deliverables
- Base Currency, Base Year and Forecast Periods
- General Study Assumptions
- Research Methodology
- Introduction
- Research Phases
- Secondary Research
- Primary Research
- Econometric Modelling
- Expert Validation
- Analysis of Design Study Timeline
- Overview
- Executive Summary
- Key Inferences
- Epidemiology
- Drivers, Restraints, Opportunities, and Challenges Analysis (DROC)
- Antibody Drug Conjugates Market Drivers
- Antibody Drug Conjugates Market Restraints
- Key Challenges
- Current Opportunities in the Antibody Drug Conjugates Market
- Antibody Drug Conjugates Market Segmentation
- Pipeline
- Introduction
- Phase
- Mode of Action
- IgG1 Antibodies
- HER2 Antibodies
- Y-o-Y Growth Analysis, By Pipeline
- Market Attractiveness Analysis, By Pipeline
- Market Share Analysis, By Pipeline
- By Technology
- Seattle Genetics
- Immunogen
- Immunomedics
- End-User
- Research institutes
- Hospitals
- Clinics
- Others
- Y-o-Y Growth Analysis, By End User
- Market Attractiveness Analysis, By End User
- Market Share Analysis, By End User
- Geographical Analysis
- Introduction
- Regional Trends
- Impact Analysis
- Y-o-Y Growth Analysis
- By Geographical Area
- By Pipeline
- By Technology
- By End-User
- Market Attractiveness Analysis
- By Geographical Area
- By Pipeline
- By Technology
- By End-User
- Market Share Analysis
- By Geographical Area
- By Pipeline
- By Technology
- By End-User
- North America
- Introduction
- United States
- Canada
- Europe
- Introduction
- U.K
- Spain
- Germany
- Italy
- France
- Asia-Pacific
- Introduction
- China
- India
- Japan
- Australia
- South Korea
- Latin America
- Introduction
- Brazil
- Argentina
- Mexico
- Rest of Latin America
- Middle East & Africa
- Introduction
- Middle-East
- Africa
- Strategic Analysis
- PESTLE analysis
- Political
- Economic
- Social
- Technological
- Legal
- Environmental
- Porter’s Five analysis
- Bargaining Power of Suppliers
- Bargaining Power of Consumers
- The threat of New Entrants
- The threat of Substitute Products and Services
- Competitive Rivalry within the Industry
- Market Leaders' Analysis
- Seattle Genetics
- Overview
- Product Analysis
- Financial analysis
- Recent Developments
- SWOT analysis
- Analyst View
- Genentech
- Takeda Pharmaceuticals
- Hoffmann-La Roche
- Bayer Healthcare
- Agensys, Inc
- Immunogen
- Novartis
- Oxford Biotherapeutic
- Synthon Biopharmaceuticals
- Competitive Landscape
- Market share analysis
- Merger and Acquisition Analysis
- Agreements, Collaborations and Joint Ventures
- New Product Launches
- Market Outlook and Investment Opportunities
Appendix
- List of Tables
- List of Figures
- Global and country-level analysis and forecasts of the study market; providing Insights on the major countries/regions in which this industry is blooming and to also identify the regions that are still untapped
- The segment-level analysis in terms Technology along with market size forecasts and estimations to detect key areas of industry growth in detail
- Identification of key drivers, restraints, opportunities and challenges (DROC) in the market and their impact on shifting market dynamics
- Study of the effect of exogenous and endogenous factors that affect the global market; which includes broadly demographic, economics, and political, among other macro-environmental factors presented in an extensive PESTLE Analysis
- Study the micro environment factors that determine the overall profitability of an Industry, using Porter’s five forces analysis for analyzing the level of competition and business strategy development
- A comprehensive list of key market players along with their product portfolio, current strategic interests, key financial information, legal issues, SWOT analysis and analyst overview to study and sustain the market environment
- Competitive landscape analysis listing out the mergers, acquisitions, collaborations in the field along with new product launches, comparative financial studies and recent developments in the market by the major companies
- An executive summary, abridging the entire report in such a way that decision-making personnel can rapidly become acquainted with background information, concise analysis and main conclusions
- Expertly devised analyst overview along with Investment opportunities to provide both individuals and organizations a strong financial foothold in the market
